 Elisa Birnbaum
Concepts (230)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rectal Neoplasms | 35 | 2023 | 121 | 2.930 |
Why?
| | Adenocarcinoma | 22 | 2023 | 801 | 0.990 |
Why?
| | Laparoscopy | 13 | 2019 | 388 | 0.780 |
Why?
| | Fecal Incontinence | 10 | 2020 | 73 | 0.780 |
Why?
| | Colorectal Surgery | 5 | 2022 | 21 | 0.720 |
Why?
| | Neoadjuvant Therapy | 11 | 2023 | 305 | 0.710 |
Why?
| | Colectomy | 11 | 2022 | 86 | 0.550 |
Why?
| | Pelvic Floor Disorders | 3 | 2020 | 9 | 0.520 |
Why?
| | Neoplasm Recurrence, Local | 17 | 2019 | 863 | 0.500 |
Why?
| | Rectal Prolapse | 5 | 2020 | 19 | 0.490 |
Why?
| | Digestive System Surgical Procedures | 6 | 2020 | 90 | 0.430 |
Why?
| | Anal Canal | 8 | 2014 | 83 | 0.430 |
Why?
| | Neoplasm Staging | 23 | 2023 | 1176 | 0.420 |
Why?
| | Proctocolectomy, Restorative | 5 | 2016 | 19 | 0.390 |
Why?
| | Anus Neoplasms | 6 | 2009 | 24 | 0.360 |
Why?
| | Rectum | 6 | 2016 | 153 | 0.340 |
Why?
| | Patient Reported Outcome Measures | 3 | 2020 | 249 | 0.330 |
Why?
| | Training Support | 1 | 2007 | 22 | 0.280 |
Why?
| | Colonic Neoplasms | 5 | 2013 | 221 | 0.270 |
Why?
| | Certification | 1 | 2007 | 89 | 0.260 |
Why?
| | Middle Aged | 51 | 2022 | 26747 | 0.260 |
Why?
| | Treatment Outcome | 31 | 2023 | 9089 | 0.260 |
Why?
| | Pelvic Floor | 3 | 2020 | 22 | 0.250 |
Why?
| | Colitis, Ulcerative | 4 | 2016 | 105 | 0.240 |
Why?
| | Postoperative Complications | 13 | 2022 | 2127 | 0.240 |
Why?
| | Retrospective Studies | 33 | 2023 | 12511 | 0.230 |
Why?
| | Aged | 40 | 2020 | 19078 | 0.230 |
Why?
| | Rectal Fistula | 4 | 2013 | 21 | 0.230 |
Why?
| | Fellowships and Scholarships | 1 | 2007 | 226 | 0.230 |
Why?
| | Preoperative Care | 7 | 2014 | 317 | 0.230 |
Why?
| | Aged, 80 and over | 28 | 2020 | 6346 | 0.220 |
Why?
| | Societies, Medical | 3 | 2020 | 663 | 0.220 |
Why?
| | Male | 57 | 2022 | 55554 | 0.220 |
Why?
| | Consensus | 3 | 2020 | 535 | 0.220 |
Why?
| | Female | 60 | 2022 | 59483 | 0.220 |
Why?
| | Colonic Pouches | 2 | 2013 | 14 | 0.200 |
Why?
| | Brachytherapy | 2 | 2001 | 104 | 0.200 |
Why?
| | Fluorouracil | 7 | 2014 | 152 | 0.200 |
Why?
| | Pelvic Organ Prolapse | 2 | 2020 | 39 | 0.190 |
Why?
| | Adult | 42 | 2020 | 30542 | 0.190 |
Why?
| | Humans | 69 | 2023 | 114709 | 0.180 |
Why?
| | Radiation Injuries | 3 | 2009 | 128 | 0.180 |
Why?
| | Manometry | 7 | 2006 | 89 | 0.170 |
Why?
| | Follow-Up Studies | 16 | 2019 | 4420 | 0.170 |
Why?
| | Pneumoperitoneum | 1 | 2019 | 11 | 0.170 |
Why?
| | Urology | 1 | 2020 | 46 | 0.160 |
Why?
| | Skiing | 1 | 2019 | 42 | 0.160 |
Why?
| | Urologic Surgical Procedures | 1 | 2020 | 94 | 0.160 |
Why?
| | Laparotomy | 2 | 2015 | 96 | 0.150 |
Why?
| | Radiotherapy | 3 | 2003 | 176 | 0.150 |
Why?
| | Disease-Free Survival | 11 | 2019 | 623 | 0.150 |
Why?
| | Radiotherapy, Adjuvant | 10 | 2019 | 182 | 0.150 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2023 | 40 | 0.150 |
Why?
| | Medicine | 1 | 2019 | 102 | 0.150 |
Why?
| | Radiotherapy Dosage | 8 | 2009 | 245 | 0.150 |
Why?
| | Combined Modality Therapy | 10 | 2016 | 1122 | 0.150 |
Why?
| | Propensity Score | 1 | 2019 | 224 | 0.150 |
Why?
| | Internship and Residency | 1 | 2007 | 932 | 0.140 |
Why?
| | Gynecology | 1 | 2020 | 163 | 0.140 |
Why?
| | Carcinoma, Squamous Cell | 5 | 2009 | 584 | 0.140 |
Why?
| | Crohn Disease | 4 | 2019 | 196 | 0.130 |
Why?
| | Surgeons | 1 | 2019 | 237 | 0.130 |
Why?
| | Perineum | 3 | 2008 | 25 | 0.130 |
Why?
| | Quality of Life | 3 | 2020 | 2356 | 0.120 |
Why?
| | Anastomotic Leak | 1 | 2014 | 27 | 0.120 |
Why?
| | Fluorodeoxyglucose F18 | 3 | 2006 | 113 | 0.110 |
Why?
| | Radiopharmaceuticals | 3 | 2006 | 157 | 0.110 |
Why?
| | Fistula | 1 | 2013 | 26 | 0.110 |
Why?
| | Colostomy | 2 | 2012 | 26 | 0.110 |
Why?
| | Prospective Studies | 10 | 2014 | 6215 | 0.110 |
Why?
| | Defecation | 1 | 1992 | 17 | 0.100 |
Why?
| | Bioprosthesis | 1 | 2012 | 36 | 0.100 |
Why?
| | Survival Analysis | 7 | 2016 | 1218 | 0.100 |
Why?
| | Postoperative Care | 1 | 2013 | 219 | 0.100 |
Why?
| | Intestinal Obstruction | 1 | 2012 | 40 | 0.100 |
Why?
| | Diverticulitis, Colonic | 1 | 2011 | 7 | 0.100 |
Why?
| | Lymphatic Metastasis | 2 | 2010 | 280 | 0.090 |
Why?
| | Chemotherapy, Adjuvant | 5 | 2023 | 333 | 0.090 |
Why?
| | Severity of Illness Index | 4 | 2013 | 2537 | 0.090 |
Why?
| | Lymph Nodes | 2 | 2011 | 423 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2014 | 1361 | 0.090 |
Why?
| | Rosaniline Dyes | 1 | 2010 | 10 | 0.090 |
Why?
| | Salvage Therapy | 2 | 2009 | 127 | 0.090 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2012 | 204 | 0.090 |
Why?
| | Coloring Agents | 1 | 2010 | 72 | 0.090 |
Why?
| | Urodynamics | 2 | 2020 | 28 | 0.080 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2010 | 100 | 0.080 |
Why?
| | Time Factors | 8 | 2015 | 6122 | 0.080 |
Why?
| | Tomography, Emission-Computed | 2 | 2000 | 58 | 0.080 |
Why?
| | Chi-Square Distribution | 4 | 2011 | 494 | 0.080 |
Why?
| | Proportional Hazards Models | 5 | 2008 | 1080 | 0.080 |
Why?
| | Chemoradiotherapy | 2 | 2023 | 190 | 0.080 |
Why?
| | Adenoma | 1 | 2010 | 189 | 0.080 |
Why?
| | Survival Rate | 5 | 2011 | 1642 | 0.080 |
Why?
| | Length of Stay | 4 | 2015 | 949 | 0.080 |
Why?
| | Colonoscopy | 1 | 2010 | 205 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 4 | 2011 | 2268 | 0.070 |
Why?
| | Ultrasonography | 4 | 2005 | 629 | 0.070 |
Why?
| | Liver Neoplasms | 2 | 2010 | 507 | 0.070 |
Why?
| | Antimetabolites, Antineoplastic | 3 | 2002 | 82 | 0.070 |
Why?
| | Intestines | 1 | 2010 | 325 | 0.070 |
Why?
| | Vaginal Fistula | 2 | 2013 | 3 | 0.070 |
Why?
| | United States | 5 | 2020 | 12175 | 0.070 |
Why?
| | Specialty Boards | 1 | 2007 | 32 | 0.070 |
Why?
| | Ileostomy | 3 | 2011 | 18 | 0.070 |
Why?
| | Drug Administration Schedule | 3 | 2014 | 718 | 0.070 |
Why?
| | Research Support as Topic | 1 | 2007 | 108 | 0.070 |
Why?
| | Anastomosis, Surgical | 3 | 2013 | 136 | 0.060 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2022 | 447 | 0.060 |
Why?
| | Ileitis | 1 | 2006 | 26 | 0.060 |
Why?
| | Recurrence | 4 | 2012 | 936 | 0.060 |
Why?
| | Mentors | 1 | 2007 | 156 | 0.060 |
Why?
| | Bowen's Disease | 1 | 2004 | 1 | 0.060 |
Why?
| | Anus Diseases | 1 | 2004 | 7 | 0.060 |
Why?
| | Positron-Emission Tomography | 1 | 2006 | 258 | 0.060 |
Why?
| | Age Factors | 4 | 2013 | 2889 | 0.060 |
Why?
| | Antineoplastic Agents | 2 | 2013 | 1895 | 0.060 |
Why?
| | Neoplasm, Residual | 2 | 2015 | 104 | 0.060 |
Why?
| | Fibrin Tissue Adhesive | 1 | 2004 | 13 | 0.060 |
Why?
| | Tissue Adhesives | 1 | 2004 | 16 | 0.060 |
Why?
| | Colitis | 1 | 2006 | 223 | 0.050 |
Why?
| | Amifostine | 1 | 2002 | 1 | 0.050 |
Why?
| | Induction Chemotherapy | 1 | 2023 | 56 | 0.050 |
Why?
| | Radiation-Protective Agents | 1 | 2002 | 26 | 0.050 |
Why?
| | Cytoprotection | 1 | 2002 | 51 | 0.050 |
Why?
| | Abdomen | 2 | 2005 | 100 | 0.050 |
Why?
| | Carcinoembryonic Antigen | 1 | 2022 | 37 | 0.050 |
Why?
| | Patient Readmission | 3 | 2013 | 608 | 0.050 |
Why?
| | Intestinal Perforation | 2 | 2012 | 38 | 0.050 |
Why?
| | Specialties, Surgical | 1 | 2002 | 70 | 0.050 |
Why?
| | Obesity | 1 | 2013 | 2513 | 0.050 |
Why?
| | Morbidity | 1 | 2022 | 277 | 0.050 |
Why?
| | Missouri | 2 | 2009 | 61 | 0.050 |
Why?
| | Pelvic Neoplasms | 1 | 2000 | 18 | 0.050 |
Why?
| | Predictive Value of Tests | 3 | 2004 | 1795 | 0.050 |
Why?
| | Analysis of Variance | 3 | 2011 | 1226 | 0.050 |
Why?
| | Databases, Factual | 2 | 2019 | 1126 | 0.040 |
Why?
| | Catheter Ablation | 1 | 2003 | 291 | 0.040 |
Why?
| | Hospitals, University | 2 | 2009 | 171 | 0.040 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2000 | 60 | 0.040 |
Why?
| | Soft Tissue Neoplasms | 1 | 2000 | 90 | 0.040 |
Why?
| | Radiotherapy, High-Energy | 1 | 1999 | 12 | 0.040 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2020 | 60 | 0.040 |
Why?
| | Constipation | 1 | 2020 | 76 | 0.040 |
Why?
| | Lower Urinary Tract Symptoms | 1 | 2020 | 48 | 0.040 |
Why?
| | Forecasting | 2 | 2013 | 331 | 0.040 |
Why?
| | Uterine Prolapse | 1 | 2018 | 11 | 0.040 |
Why?
| | Leucovorin | 2 | 2014 | 43 | 0.040 |
Why?
| | Patient Selection | 2 | 1999 | 641 | 0.040 |
Why?
| | Sensitivity and Specificity | 4 | 2010 | 1690 | 0.040 |
Why?
| | Statistics, Nonparametric | 2 | 2010 | 386 | 0.040 |
Why?
| | Pelvis | 2 | 2011 | 90 | 0.040 |
Why?
| | Colon | 1 | 2019 | 233 | 0.040 |
Why?
| | Skin Neoplasms | 1 | 2004 | 761 | 0.040 |
Why?
| | Endoscopy | 1 | 1999 | 248 | 0.030 |
Why?
| | HIV Seropositivity | 2 | 2009 | 109 | 0.030 |
Why?
| | Ploidies | 1 | 1996 | 17 | 0.030 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 1996 | 49 | 0.030 |
Why?
| | S Phase | 1 | 1996 | 70 | 0.030 |
Why?
| | Treatment Failure | 3 | 2007 | 332 | 0.030 |
Why?
| | Rectal Diseases | 1 | 1996 | 17 | 0.030 |
Why?
| | Colonic Diseases | 1 | 1996 | 25 | 0.030 |
Why?
| | Pressure | 1 | 1996 | 218 | 0.030 |
Why?
| | Palliative Care | 3 | 2012 | 641 | 0.030 |
Why?
| | Sensory Thresholds | 1 | 1994 | 28 | 0.030 |
Why?
| | Reflex | 1 | 1994 | 64 | 0.030 |
Why?
| | Organoplatinum Compounds | 1 | 2014 | 37 | 0.030 |
Why?
| | Organ Sparing Treatments | 1 | 2014 | 31 | 0.030 |
Why?
| | Pouchitis | 1 | 2013 | 5 | 0.030 |
Why?
| | Urinary Bladder Fistula | 1 | 2013 | 10 | 0.030 |
Why?
| | Cutaneous Fistula | 1 | 2013 | 13 | 0.030 |
Why?
| | Constriction, Pathologic | 1 | 2013 | 208 | 0.030 |
Why?
| | Quality Improvement | 1 | 2020 | 951 | 0.030 |
Why?
| | Prognosis | 4 | 2004 | 3334 | 0.020 |
Why?
| | Intestine, Small | 1 | 2012 | 122 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2013 | 220 | 0.020 |
Why?
| | Prosthesis Implantation | 1 | 2012 | 139 | 0.020 |
Why?
| | Colorectal Neoplasms | 1 | 1997 | 621 | 0.020 |
Why?
| | Incidence | 2 | 2008 | 2312 | 0.020 |
Why?
| | Abscess | 1 | 2011 | 72 | 0.020 |
Why?
| | Pyridines | 1 | 2014 | 425 | 0.020 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2010 | 32 | 0.020 |
Why?
| | Contraindications | 1 | 2010 | 85 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 1996 | 1053 | 0.020 |
Why?
| | Hepatectomy | 1 | 2010 | 119 | 0.020 |
Why?
| | Mitomycin | 1 | 2009 | 27 | 0.020 |
Why?
| | Lymph Node Excision | 1 | 2010 | 141 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2016 | 3004 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 815 | 0.020 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2009 | 66 | 0.020 |
Why?
| | Chronic Disease | 1 | 1994 | 1590 | 0.020 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2009 | 52 | 0.020 |
Why?
| | Acute Disease | 1 | 2011 | 912 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2008 | 445 | 0.020 |
Why?
| | Intraoperative Complications | 2 | 1999 | 121 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2010 | 1435 | 0.020 |
Why?
| | Risk Factors | 2 | 2013 | 8625 | 0.020 |
Why?
| | Inguinal Canal | 1 | 2006 | 7 | 0.020 |
Why?
| | Adolescent | 3 | 2010 | 17806 | 0.020 |
Why?
| | Body Mass Index | 1 | 2013 | 1958 | 0.020 |
Why?
| | Pain Measurement | 1 | 2008 | 445 | 0.020 |
Why?
| | Proctoscopy | 1 | 2005 | 6 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2010 | 1635 | 0.020 |
Why?
| | Blood Loss, Surgical | 1 | 2005 | 84 | 0.020 |
Why?
| | Research Design | 1 | 2010 | 931 | 0.010 |
Why?
| | Young Adult | 2 | 2010 | 10461 | 0.010 |
Why?
| | Anesthesia, Local | 1 | 2003 | 15 | 0.010 |
Why?
| | Remission Induction | 1 | 2004 | 233 | 0.010 |
Why?
| | Washington | 1 | 2003 | 134 | 0.010 |
Why?
| | Texas | 1 | 2003 | 188 | 0.010 |
Why?
| | Carcinoma | 1 | 2004 | 198 | 0.010 |
Why?
| | Blood Transfusion | 1 | 2005 | 276 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 2003 | 372 | 0.010 |
Why?
| | Wound Healing | 1 | 2004 | 258 | 0.010 |
Why?
| | Biopsy | 1 | 2004 | 1040 | 0.010 |
Why?
| | Academic Medical Centers | 1 | 2003 | 413 | 0.010 |
Why?
| | Outpatients | 1 | 2003 | 327 | 0.010 |
Why?
| | Sex Factors | 1 | 2005 | 1717 | 0.010 |
Why?
| | Vagina | 1 | 1999 | 146 | 0.010 |
Why?
| | Antidotes | 1 | 1999 | 135 | 0.010 |
Why?
| | Radiation Tolerance | 1 | 1996 | 92 | 0.010 |
Why?
| | Neoplasm Metastasis | 1 | 1997 | 528 | 0.010 |
Why?
| | Cohort Studies | 1 | 2005 | 4899 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 1999 | 1340 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2005 | 3031 | 0.010 |
Why?
| | Feasibility Studies | 1 | 1997 | 737 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2005 | 4621 | 0.010 |
Why?
| | Inflammatory Bowel Diseases | 1 | 1997 | 283 | 0.010 |
Why?
| | Reaction Time | 1 | 1994 | 375 | 0.010 |
Why?
| | Melanoma | 1 | 1997 | 629 | 0.010 |
Why?
|
|
Birnbaum's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|